|
|
胶质母细胞瘤的最新治疗进展
|
Abstract:
胶质母细胞瘤是中枢神经系统中最常见和高度恶性的原发性肿瘤。经过多年的研究，胶质母细胞瘤的治疗取得了各种治疗的进展。目前，胶质母细胞瘤的治疗是基于最大限度的安全手术切除，放射治疗和替莫唑胺的化疗。最近，贝伐单抗及肿瘤治疗电场已被加入到治疗。然而，胶质母细胞瘤患者仍然预后不佳。因此，在不同的临床研究领域正在做出许多努力寻找一种新的替代方法来改善胶质母细胞瘤患者的总生存率、无进展生存率和生活质量。
Glioblastoma is the most common and highly malignant primary neoplasm in the central nervous system. After many years of research, the treatment of glioblastoma has made progress in various treatments. Currently, the treatment of glioblastoma is based on maximal safe surgical resection, radiotherapy, and chemotherapy with temozolomide. Recently, bevacizumab and tumor treatment electric fields have been added to the treatment. However, patients with glioblastoma still have a poor prognosis. Therefore, many efforts are being made in different clinical research areas to find a new alternative approach to improve overall survival, progression-free survival and quality of life in patients with glioblastoma.
| [1] | Stupp, R., Mason, W.P., van den Bent, M.J., Weller, M., Fisher, B., Taphoorn, M.J., et al. (2005) Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. The New England Journal of Medicine, 352, 987-996.
https://doi.org/10.1056/NEJMoa043330 |
| [2] | Tan, A.C., Ashley, D.M., López, G.Y., Malinzak, M., Friedman, H.S. and Khasraw, M. (2020) Management of Glioblastoma: State of the Art and Future Directions. CA: A Cancer Jour-nal for Clinicians, 70, 299-312.
https://doi.org/10.3322/caac.21613 |
| [3] | Davis, M.E. (2016) Glioblastoma: Overview of Disease and Treatment. Clinical Journal of Oncology Nursing, 20, S2-S8. https://doi.org/10.1188/16.CJON.S1.2-8 |
| [4] | Altshuler, D.B., Kadiyala, P., Nu？ez, F.J., Nu？ez, F.M., Carney, S., Alghamri, M.S., et al. (2020) Prospects of Biological and Synthetic Pharmacotherapies for Glioblastoma. Expert Opinion on Biological Therapy, 20, 305-317.
https://doi.org/10.1080/14712598.2020.1713085 |
| [5] | Le Rhun, E., Preusser, M., Roth, P., Reardon, D.A., van den Bent, M., Wen, P., Reifenberger, G. and Weller, M. (2019) Molecular Targeted Therapy of Glioblastoma. Cancer Treatment Reviews, 80, Article ID: 101896.
https://doi.org/10.1016/j.ctrv.2019.101896 |
| [6] | Bush, N.A., Chang, S.M. and Berger, M.S. (2017) Current and Future Strategies for Treatment of Glioma. Neurosurgical Review, 40, 1-14. https://doi.org/10.1007/s10143-016-0709-8 |
| [7] | Dilmen, O.K., Akcil, E.F., Oguz, A., Vehid, H. and Tunali, Y. (2017) Comparison of Conscious Sedation and Asleep-Awake-Asleep Techniques for Awake Craniotomy. Journal of Clinical Neuroscience, 35, 30-34.
https://doi.org/10.1016/j.jocn.2016.10.007 |
| [8] | Chelliah, S.S., Paul, E.A.L., Kamarudin, M.N.A. and Parhar, I. (2021) Challenges and Perspectives of Standard Therapy and Drug Development in High-Grade Gliomas. Molecules, 26, 1169. https://doi.org/10.3390/molecules26041169 |
| [9] | Chowdhury, T., Singh, G.P., Zeiler, F.A., Hailu, A., Loe-wen, H., Schaller, B., Cappellani, R.B. and West, M. (2018) Anesthesia for Awake Craniotomy for Brain Tumors in an Intraoperative MRI Suite: Challenges and Evidence. Frontiers in Oncology, 8, 519. https://doi.org/10.3389/fonc.2018.00519 |
| [10] | 叶新运. 神经导航联合“黄荧光”技术在胶质瘤手术治疗中的应用[C]//中国医师协会, 中国医师协会神经外科医师分会. 第十六届中国医师协会神经外科医师年会摘要集. [出版者不详], 2022: 2.
https://doi.org/10.26914/c.cnkihy.2022.033401 |
| [11] | 张义松, 张晓军, 韩志桐, 等. 神经导航联合显微镜下荧光素钠引导手术治疗成人胶质瘤的疗效及预后分析(附45例报告) [J]. 现代肿瘤医学, 2022, 30(16): 2918-2922. |
| [12] | Garzon-Muvdi, T., Kut, C., Li, X. and Chaichana, K.L. (2017) Intraoperative Imaging Techniques for Glioma Surgery. Future Oncology, 13, 1731-1745. https://doi.org/10.2217/fon-2017-0092 |
| [13] | Frosina, G. (2021) Radiotherapy of High-Grade Gliomas: First Half of 2021 Update with Special Reference to Radiosensitization Studies. International Journal of Molecular Sciences, 22, 8942. https://doi.org/10.3390/ijms22168942 |
| [14] | Stupp, R., Tail-libert, S., Kanner, A., Read, W., Steinberg, D., Lhermitte, B., et al. (2017) Effect of Tumor-Treating Fields plus Mainte-nance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients with Glioblastoma: A Randomized Clinical Trial. JAMA, 318, 2306-2316. https://doi.org/10.1001/jama.2017.18718 |
| [15] | Weller, M., van den Bent, M., Preusser, M., Le Rhun, E., Tonn, J.C., Minniti, G., et al. (2021) EANO Guidelines on the Diagnosis and Treatment of Diffuse Gliomas of Adulthood. Nature Reviews Clinical Oncology, 18, 170-186.
https://doi.org/10.1038/s41571-020-00447-z |
| [16] | Chinot, O.L., Wick, W., Mason, W., Henriksson, R., Saran, F., Nishikawa, R., et al. (2014) Bevacizumab plus Radiotherapy-Temozolomide for Newly Diagnosed Glioblastoma. The New England Journal of Medicine, 370, 709-722.
https://doi.org/10.1056/NEJMoa1308345 |
| [17] | Desbaillets, N. and Hottinger, A.F. (2021) Immunotherapy in Glio-blastoma: A Clinical Perspective. Cancers, 13, 3721.
https://doi.org/10.3390/cancers13153721 |
| [18] | Khaddour, K., Johanns, T.M. and Ansstas, G. (2020) The Land-scape of Novel Therapeutics and Challenges in Glioblastoma Multiforme: Contemporary State and Future Directions. Pharmaceuticals (Basel), 13, 389.
https://doi.org/10.3390/ph13110389 |
| [19] | Huang, B., Zhang, H., Gu, L., Ye, B., Jian, Z., Stary, C. and Xiong, X. (2017) Advances in Immunotherapy for Glioblastoma Multiforme. Journal of Immunology Research, 2017, Article ID: 3597613.
https://doi.org/10.1155/2017/3597613 |
| [20] | Suryawanshi, Y.R. and Schulze, A.J. (2021) Oncolytic Viruses for Malignant Glioma: On the Verge of Success? Viruses, 13, 1294. https://doi.org/10.3390/v13071294 |
| [21] | Zeng, J., Li, X., Sander, M., Zhang, H., Yan, G. and Lin, Y. (2021) Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas. Frontiers in Immunology, 12, Article ID: 721830.
https://doi.org/10.3389/fimmu.2021.721830 |
| [22] | Bai, Y., Hui, P., Du, X. and Su, X. (2019) Updates to the Anti-tumor Mechanism of Oncolytic Virus. Thoracic Cancer, 10, 1031-1035. https://doi.org/10.1111/1759-7714.13043 |
| [23] | Wollmann, G., Ozduman, K. and van den Pol, A.N. (2012) Onco-lytic Virus Therapy for Glioblastoma Multiforme: Concepts and Candidates. The Cancer Journal, 18, 69-81. https://doi.org/10.1097/PPO.0b013e31824671c9 |
